Sources: Genzyme proposes contingent-value deal for sale of shares

11/22/2010 | Wall Street Journal, The

Genzyme, which continues to reject a $69-per-share bid by Sanofi-Aventis, is considering using a contingent-value right, a deal structure that might end the takeover deadlock, sources said. The structure gives shareholders a financial benefit if the acquired company reaches certain milestones. Genzyme reportedly is also integrating the structure in talks with other potential buyers.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC